203435-09-0

Basic information

• Product Name: 2,3,4,6-tetra-O-benzoyl-α,b-D-galactopyranosyl trichloroacetimidate
• Synonyms: 2,3,4,6-tetra-O-benzoyl-α,b-D-galactopyranosyl trichloroacetimidate
• CAS NO: 203435-09-0
• Molecular Weight: 740.978
• Mol File: 203435-09-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2,3,4,6-tetra-O-benzoyl-α,b-D-galactopyranosyl trichloroacetimidate(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4,6-tetra-O-benzoyl-α,b-D-galactopyranosyl trichloroacetimidate(203435-09-0)
• EPA Substance Registry System: 2,3,4,6-tetra-O-benzoyl-α,b-D-galactopyranosyl trichloroacetimidate(203435-09-0)

Safety Data

• Hazardous Substances Data: 203435-09-0(Hazardous Substances Data)

Upstream product

• 48149-72-0 (2S,3R,4S,5R,6R)-2-Allyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol 
• 627466-84-6 2,3,4,6-tetra-O-benzoyl-D-galactose 
• 545-06-2 trichloroacetonitrile 
• 98-88-4 benzoyl chloride 
• 2592-58-7 1,2,3,4,6-Penta-O-benzoyl-α-D-galactopyranose 
• 10257-28-0 D-Galactose 
• 188435-38-3 bromide 2,3,4,6-tetra-O-Bz-α-D-galactopyranosyl bromide 

Downstream Products

• 162710-64-7 O-(2,3,4,6-Tetra-O-benzoyl-β-D-galactopyranosyl)-(1->4)-1,6-anhydro-2,3-O-endo/exo-benzylidene-β-D-mannopyranose 
• 162710-57-8 O-(2,3,4,6-Tetra-O-benzoyl-β-D-galactopyranosyl)-(1->4)-1,6-anhydro-endo-2,3-O-(4-methoxybenzylidene)-β-D-mannopyranose 
• 203435-15-8 benzyl O-(2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1->4)-2-acetamido-3-O-allyl-2-deoxy-6-O-(p-methoxyphenyl)-β-D-allopyranoside 
• 215302-36-6 octyl O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-(1->3)-O-[(2,3,4,6-tetra-O-benzoyl)-β-D-galactopyranosyl-(1->6)]-2-acetamido-2-deoxy-α-D-glucopyranoside 
• 293752-49-5 (1R,2R) 2-hydroxy-cyclohexyl 2,3,4,6-tetra-O-benzoyl-β-D-galactopyranoside 
• 493027-47-7 C₆₂H₆₁NO₁₇Si 
• 885453-86-1 gitotenin 2α-O-benzyl-3β-O-(2,3,4,6-tetra-O-benzoyl-β-D-galactopyranoside) 
• 904691-44-7 phenyl (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1->6)-2,3,4-tri-O-benzoyl-1-thio-α-D-mannopyranoside 
• 904691-46-9 C₆₃H₅₀Cl₃NO₁₈ 
• 904691-47-0 [2-(methyl-4-carbamoylbutanoyl)ethyl] (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1->6)-2,3,4-tri-O-benzoyl-1-thio-α-D-mannopyranoside 
• 493027-48-8 C₅₉H₄₉Cl₃N₂O₁₇ 
• 294677-28-4 (1R,2R) 2-hydroxy-cyclohexyl β-D-galactopyranoside 
• 293752-50-8 (1R,2R) 2-hydroxy-cyclohexyl 3-O-[2-O-(5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosonate)]-β-D-galactopyranoside 

Relevant articles and documents

Carbon tetrachloride-free allylic halogenation-mediated glycosylations of allyl glycosides

The allylic bromination of allyl glycosides is conducted using NBS/AIBN reagents in (EtO)2CO and PhCF3 solutions, without using CCl4 as a solvent. The activated mixed halo-allyl glycosides led to glycosylations, mediated by a triflate, in a latent-active

Synthesis of a chlorogenin glycoside library using an orthogonal protecting group strategy

Naturally occurring spirostanol saponins bear a chacotriose, α-l-rhamnopyranosyl-(1→2)-[α-l-rhamnopyranosyl-(1→4)] -β-d-glucopyranose residue as the oligosaccharide moiety which is believed to be important for biological activity. Herein the development of a concise, combinatorial method for the synthesis of two series of glycan variants at the 2′ and/or 4′ positions of chacotriose is described and the structure-activity relationships of the glycone part at 3-OH of chlorogenin investigated. These compounds were found to be weakly-cytotoxic toward leukemia cell lines CCRF and HL-20, indicating that the chacotriose moiety is important for anticancer activity.

TRITERPENES DERIVATIVES AND USES THEREOF AS ANTITUMOR AGENTS OR ANTI-INFLAMMATORY AGENTS

A compound of formula (1): wherein R1 is selected from the group consisting of H, α-L-Rhamnopyranose, α-D-Mannopyranose, β-D-Xylopyranose, β-D-Glucopyranose, and α-D-Arabinopyranose; R2 is selected from CH3, COOH, CH2OH, COOCH3 and CH2O-α-D-Arabinopyranose; with the proviso that the compound of formula (I) is not a compound of formula (I) wherein R1 is β-D-Glucopyranose and R2 is COOH; wherein R1 is α-L-Rhamnopyranose and R2 is CH3; wherein R1 is β-D-Glucopyranose and R2 is CH2OH; wherein R1 is β-D-Xylopyranose and R2 is CH2OH; wherein R1 is α-L-Rhamnopyranose and R2 is COOCH3, wherein R1 is H and R2 is CH3; wherein R1 is H and R2 is CH2OH; wherein R1 is H and R2 is COOH; or wherein R1 is H and R2 is COOCH3, or a pharmaceutically acceptable salt thereof.